In this Q&A, Sara Reece, PharmD, CDCES, discusses the use of GLP-1 agonists and SGLT-2 inhibitors to improve cardiovascular and renal outcomes in patients with type 2 diabetes.
In this Q&A, Sara Reece, PharmD, CDCES, discusses the use of GLP-1 agonists and SGLT-2 inhibitors to improve cardiovascular and renal outcomes in patients with type 2 diabetes.
Dr Jonathan Repple
In this Q&A, Jonathan Repple, MD, professor of predictive psychiatry at the University of Frankfurt, Germany, discussed his most recent study presented on a poster at the 35th...
Monica Gandhi, MD, MPH, infectious disease doctor and director of the Center for AIDS Research at University of California–San Francisco, discusses medication therapies in the pipeline that could change the...
Elizabeth Volkmann, MD, associate professor at UCLA, Director of the Scleroderma Program, and the codirector of UCLA's Connective Tissue Disease-Related Interstitial Lung Disease program, discusses treating...
Elizabeth Volkmann, MD, associate professor at UCLA, Director of the Scleroderma Program, and the codirector of UCLA's Connective Tissue Disease-Related Interstitial Lung Disease program, discusses treating...
Elizabeth Volkmann, MD, associate professor at UCLA, Director of the Scleroderma Program, and the codirector of UCLA's Connective Tissue Disease-Related Interstitial Lung Disease program, discusses treating...
Elizabeth Volkmann, MD, associate professor at UCLA, Director of the Scleroderma Program, and the codirector of UCLA's Connective Tissue Disease-Related Interstitial Lung Disease program, discusses treating...
